Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Coya Therapeutics, Inc.COYA · Entity 6727 | Director | January 01, 2024 | January 19, 2024 |
| PROTHENA CORP PUBLIC LTD COPRTA · Entity 2375 | Chief Medical Officer | February 27, 2024 | February 29, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Coya Therapeutics, Inc.
Report date January 01, 2024 · Filed January 19, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.41 · Expires 2034-01-01 | Direct | 5,000 |
Reported balance
After 2024-01-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-01-01 · Grant · Acquired 5,000 · Balance 5,000 F1: Subject to continuous service, 100% of the option will vest on the first anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Subject to continuous service, 100% of the option will vest on the first anniversary of the date of grant.
PROTHENA CORP PUBLIC LTD CO
Report date February 27, 2024 · Filed February 29, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.30 · Expires 2034-02-27 | Direct | 85,000 |
Reported balance
After 2024-02-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-02-27 · Grant · Acquired 85,000 · Balance 85,000 F1: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on February 27, 2025, and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on February 27, 2025, and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 27, 2024 Filed Feb 29, 2024 21:01 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantStock Option (Right to Buy) · Derivative | 85,000 | $0.00 Strike: $30.30 | $0.00 |
DisclosureSEC source: 0000905148-24-000834 · form4.xml · derivative · entry 1 Garren Hideki · CIK 0001854126 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,000 Underlying: Ordinary Shares · 85,000 shares Expires 2034-02-27 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on February 27, 2025, and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| January 01, 2024 Filed Jan 19, 2024 18:30 UTC | Coya Therapeutics, Inc. COYA · Entity 6727 | GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $7.41 | $0.00 |
DisclosureSEC source: 0001493152-24-003111 · ownership.xml · derivative · entry 1 Garren Hideki · CIK 0001854126 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock, par value $0.0001 per share · 5,000 shares Expires 2034-01-01 F1 · derivative.exercise_date: Subject to continuous service, 100% of the option will vest on the first anniversary of the date of grant. Read SEC document |
| September 13, 2023 Filed Sep 13, 2023 19:33 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $24.90 | $0.00 |
DisclosureSEC source: 0000905148-23-000919 · form4.xml · derivative · entry 3 Garren Hideki · CIK 0001854126 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 192,000 Underlying: Ordinary Shares · 2,000 shares Expires 2031-04-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to the option vested and became exercisable as to 25% of the total number of shares subject to the option on April 5, 2022, and vest and become exercisable with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| September 13, 2023 Filed Sep 13, 2023 19:33 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 2,000 | $55.48 | $110,952.20 |
DisclosureSEC source: 0000905148-23-000919 · form4.xml · nonDerivative · entry 2 Garren Hideki · CIK 0001854126 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 16, 2023. F2 · price: This transaction was executed in multiple trades in prices ranging from $54.995 to $55.96, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in footnote 2 of this Form 4. Read SEC document |
| September 13, 2023 Filed Sep 13, 2023 19:33 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionOrdinary Shares, par value $0.01 per share | 2,000 | $24.90 | $49,800.00 |
DisclosureSEC source: 0000905148-23-000919 · form4.xml · nonDerivative · entry 1 Garren Hideki · CIK 0001854126 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 16, 2023 Filed Aug 16, 2023 21:15 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $24.90 | $0.00 |
DisclosureSEC source: 0001140361-23-040143 · form4.xml · derivative · entry 5 Garren Hideki · CIK 0001854126 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 194,000 Underlying: Ordinary Shares · 2,000 shares Expires 2031-04-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The shares subject to the option vested and became exercisable as to 25% of the total number of shares subject to the option on April 5, 2022, and vest and become exercisable with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| August 16, 2023 Filed Aug 16, 2023 21:15 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 374 | $59.74 | $22,341.45 |
DisclosureSEC source: 0001140361-23-040143 · form4.xml · nonDerivative · entry 4 Garren Hideki · CIK 0001854126 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 16, 2023. F4 · price: The transaction was executed in multiple trades in prices ranging from $59.65 to $60.26, inclusive. Read SEC document |
| August 16, 2023 Filed Aug 16, 2023 21:15 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 748 | $58.93 | $44,079.19 |
DisclosureSEC source: 0001140361-23-040143 · form4.xml · nonDerivative · entry 3 Garren Hideki · CIK 0001854126 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 374 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 16, 2023. F3 · price: The transaction was executed in multiple trades in prices ranging from $58.585 to $59.24, inclusive. Read SEC document |
| August 16, 2023 Filed Aug 16, 2023 21:15 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 878 | $58.15 | $51,059.39 |
DisclosureSEC source: 0001140361-23-040143 · form4.xml · nonDerivative · entry 2 Garren Hideki · CIK 0001854126 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,122 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 16, 2023. F2 · price: The transaction was executed in multiple trades in prices ranging from $57.555 to $58.545, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the ranges set forth in footnotes 2 through 4 of this Form 4. Read SEC document |
| August 16, 2023 Filed Aug 16, 2023 21:15 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionOrdinary Shares, par value $0.01 per share | 2,000 | $24.90 | $49,800.00 |
DisclosureSEC source: 0001140361-23-040143 · form4.xml · nonDerivative · entry 1 Garren Hideki · CIK 0001854126 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 12, 2023 Filed Jul 12, 2023 20:45 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $24.90 | $0.00 |
DisclosureSEC source: 0001140361-23-034304 · form4.xml · derivative · entry 4 Garren Hideki · CIK 0001854126 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 196,000 Underlying: Ordinary Shares · 2,000 shares Expires 2031-04-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the option vested and became exercisable as to 25% of the total number of shares subject to the option on April 5, 2022, and vest and become exercisable with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| July 12, 2023 Filed Jul 12, 2023 20:45 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 92 | $68.20 | $6,274.00 |
DisclosureSEC source: 0001140361-23-034304 · form4.xml · nonDerivative · entry 3 Garren Hideki · CIK 0001854126 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 16, 2023. F3 · price: The transaction was executed in multiple trades in prices ranging from $68.12 to $68.20, inclusive. Read SEC document |
| July 12, 2023 Filed Jul 12, 2023 20:45 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 1,908 | $67.48 | $128,752.60 |
DisclosureSEC source: 0001140361-23-034304 · form4.xml · nonDerivative · entry 2 Garren Hideki · CIK 0001854126 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 92 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 16, 2023. F2 · price: The transaction was executed in multiple trades in prices ranging from $66.94 to $67.86, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the ranges set forth in footnotes 2 through 3 of this Form 4. Read SEC document |
| July 12, 2023 Filed Jul 12, 2023 20:45 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionOrdinary Shares, par value $0.01 per share | 2,000 | $24.90 | $49,800.00 |
DisclosureSEC source: 0001140361-23-034304 · form4.xml · nonDerivative · entry 1 Garren Hideki · CIK 0001854126 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 16, 2023 Filed Jun 16, 2023 19:31 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,331 | $0.00 Strike: $24.90 | $0.00 |
DisclosureSEC source: 0001140361-23-030333 · form4.xml · derivative · entry 3 Garren Hideki · CIK 0001854126 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 198,000 Underlying: Ordinary Shares · 7,331 shares Expires 2031-04-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares subject to the option vested and became exercisable as to 25% of the total number of shares subject to the option on April 5, 2022, and vest and become exercisable with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| June 16, 2023 Filed Jun 16, 2023 19:31 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 7,331 | $74.00 | $542,494.00 |
DisclosureSEC source: 0001140361-23-030333 · form4.xml · nonDerivative · entry 2 Garren Hideki · CIK 0001854126 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 16, 2023. Read SEC document |
| June 16, 2023 Filed Jun 16, 2023 19:31 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionOrdinary Shares, par value $0.01 per share | 7,331 | $24.90 | $182,541.90 |
DisclosureSEC source: 0001140361-23-030333 · form4.xml · nonDerivative · entry 1 Garren Hideki · CIK 0001854126 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,331 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 14, 2023 Filed Jun 14, 2023 21:15 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,669 | $0.00 Strike: $24.90 | $0.00 |
DisclosureSEC source: 0001140361-23-029929 · form4.xml · derivative · entry 6 Garren Hideki · CIK 0001854126 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 205,331 Underlying: Ordinary Shares · 4,669 shares Expires 2031-04-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The shares subject to the option vested and became exercisable as to 25% of the total number of shares subject to the option on April 5, 2022, and vest and become exercisable with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| June 14, 2023 Filed Jun 14, 2023 21:15 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 655 | $75.49 | $49,443.20 |
DisclosureSEC source: 0001140361-23-029929 · form4.xml · nonDerivative · entry 5 Garren Hideki · CIK 0001854126 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 16, 2023. F5 · price: The transaction was executed in multiple trades in prices ranging from $75.26 to $76.20, inclusive. Read SEC document |
| June 14, 2023 Filed Jun 14, 2023 21:15 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 2,534 | $74.59 | $189,009.79 |
DisclosureSEC source: 0001140361-23-029929 · form4.xml · nonDerivative · entry 4 Garren Hideki · CIK 0001854126 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 655 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 16, 2023. F4 · price: The transaction was executed in multiple trades in prices ranging from $74.16 to $75.13, inclusive. Read SEC document |
| June 14, 2023 Filed Jun 14, 2023 21:15 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 971 | $73.31 | $71,183.82 |
DisclosureSEC source: 0001140361-23-029929 · form4.xml · nonDerivative · entry 3 Garren Hideki · CIK 0001854126 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,189 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 16, 2023. F3 · price: The transaction was executed in multiple trades in prices ranging from $73.03 to $73.995, inclusive. Read SEC document |
| June 14, 2023 Filed Jun 14, 2023 21:15 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 509 | $72.45 | $36,879.04 |
DisclosureSEC source: 0001140361-23-029929 · form4.xml · nonDerivative · entry 2 Garren Hideki · CIK 0001854126 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,160 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 16, 2023. F2 · price: The transaction was executed in multiple trades in prices ranging from $71.96 to $72.91, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in footnotes 2 through 5 of this Form 4. Read SEC document |
| June 14, 2023 Filed Jun 14, 2023 21:15 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionOrdinary Shares, par value $0.01 per share | 4,669 | $24.90 | $116,258.10 |
DisclosureSEC source: 0001140361-23-029929 · form4.xml · nonDerivative · entry 1 Garren Hideki · CIK 0001854126 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,669 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 15, 2023 Filed Mar 17, 2023 21:30 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $24.90 | $0.00 |
DisclosureSEC source: 0001567619-23-005288 · doc1.xml · derivative · entry 4 Garren Hideki · CIK 0001854126 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,000 Underlying: Ordinary Shares · 12,000 shares Expires 2031-04-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the option vested and became exercisable as to 25% of the total number of shares subject to the option on April 5, 2022, and vest and become exercisable with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| March 15, 2023 Filed Mar 17, 2023 21:30 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 6,000 | $48.66 | $291,969.60 |
DisclosureSEC source: 0001567619-23-005288 · doc1.xml · nonDerivative · entry 3 Garren Hideki · CIK 0001854126 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The transaction was executed in multiple trades in prices ranging from $48.44 to $49.06, inclusive. Read SEC document |
| March 15, 2023 Filed Mar 17, 2023 21:30 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 6,000 | $48.16 | $288,966.00 |
DisclosureSEC source: 0001567619-23-005288 · doc1.xml · nonDerivative · entry 2 Garren Hideki · CIK 0001854126 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $47.43 to $48.42, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in footnotes 2 through 3 of this Form 4. Read SEC document |
| March 15, 2023 Filed Mar 17, 2023 21:30 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionOrdinary Shares, par value $0.01 per share | 12,000 | $24.90 | $298,800.00 |
DisclosureSEC source: 0001567619-23-005288 · doc1.xml · nonDerivative · entry 1 Garren Hideki · CIK 0001854126 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 02, 2023 Filed Mar 3, 2023 21:30 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantStock Option (Right to Buy) · Derivative | 48,000 | $0.00 Strike: $52.97 | $0.00 |
DisclosureSEC source: 0001140361-23-010182 · form4.xml · derivative · entry 1 Garren Hideki · CIK 0001854126 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,000 Underlying: Ordinary Shares · 48,000 shares Expires 2033-03-02 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on March 2, 2024 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| January 03, 2023 Filed Jan 4, 2023 08:30 UTC | Coya Therapeutics, Inc. COYA · Entity 6727 | PurchaseWarrant to Purchase Common Stock · Derivative | 1,000 | Not disclosed Strike: $7.50 | Not disclosed |
DisclosureSEC source: 0001493152-23-000223 · ownership.xml · derivative · entry 2 Garren Hideki · CIK 0001854126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 Underlying: Common Stock, par value $0.0001 per share · 1,000 shares Expires 2025-01-03 F1 · price: Reporting Person purchased 2,000 shares of Common Stock and an accompanying warrant to purchase 1,000 shares of Common Stock in the Issuer's initial public offering at a combined purchase price of $5.00 per share and accompanying warrant. Read SEC document |
| January 03, 2023 Filed Jan 4, 2023 08:30 UTC | Coya Therapeutics, Inc. COYA · Entity 6727 | PurchaseCommon Stock, par value $0.0001 per share | 2,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-23-000223 · ownership.xml · nonDerivative · entry 1 Garren Hideki · CIK 0001854126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 F1 · price: Reporting Person purchased 2,000 shares of Common Stock and an accompanying warrant to purchase 1,000 shares of Common Stock in the Issuer's initial public offering at a combined purchase price of $5.00 per share and accompanying warrant. Read SEC document |
| December 01, 2022 Filed Dec 2, 2022 21:30 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,000 | $0.00 Strike: $24.90 | $0.00 |
DisclosureSEC source: 0001140361-22-044320 · form4.xml · derivative · entry 3 Garren Hideki · CIK 0001854126 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,000 Underlying: Ordinary Shares · 4,000 shares Expires 2031-04-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares subject to the option vested and became exercisable as to 25% of the total number of shares subject to the option on April 5, 2022, and vest and become exercisable with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| December 01, 2022 Filed Dec 2, 2022 21:30 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 4,000 | $62.51 | $250,040.00 |
DisclosureSEC source: 0001140361-22-044320 · form4.xml · nonDerivative · entry 2 Garren Hideki · CIK 0001854126 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| December 01, 2022 Filed Dec 2, 2022 21:30 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionOrdinary Shares, par value $0.01 per share | 4,000 | $24.90 | $99,600.00 |
DisclosureSEC source: 0001140361-22-044320 · form4.xml · nonDerivative · entry 1 Garren Hideki · CIK 0001854126 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 01, 2022 Filed Nov 3, 2022 21:30 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,000 | $0.00 Strike: $24.90 | $0.00 |
DisclosureSEC source: 0001140361-22-039910 · form4.xml · derivative · entry 4 Garren Hideki · CIK 0001854126 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 226,000 Underlying: Ordinary Shares · 4,000 shares Expires 2031-04-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the option vested and became exercisable as to 25% of the total number of shares subject to the option on April 5, 2022, and vest and become exercisable with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| November 01, 2022 Filed Nov 3, 2022 21:30 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 511 | $62.41 | $31,891.97 |
DisclosureSEC source: 0001140361-22-039910 · form4.xml · nonDerivative · entry 3 Garren Hideki · CIK 0001854126 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The transaction was executed in multiple trades in prices ranging from $62.22 to $62.59, inclusive. Read SEC document |
| November 01, 2022 Filed Nov 3, 2022 21:30 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 3,489 | $61.82 | $215,682.65 |
DisclosureSEC source: 0001140361-22-039910 · form4.xml · nonDerivative · entry 2 Garren Hideki · CIK 0001854126 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 511 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $61.21 to $62.20, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in footnotes 2 through 3 of this Form 4. Read SEC document |
| November 01, 2022 Filed Nov 3, 2022 21:30 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionOrdinary Shares, par value $0.01 per share | 4,000 | $24.90 | $99,600.00 |
DisclosureSEC source: 0001140361-22-039910 · form4.xml · nonDerivative · entry 1 Garren Hideki · CIK 0001854126 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:46 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,000 | $0.00 Strike: $24.90 | $0.00 |
DisclosureSEC source: 0001567619-22-018292 · doc1.xml · derivative · entry 3 Garren Hideki · CIK 0001854126 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,000 Underlying: Ordinary Shares · 4,000 shares Expires 2031-04-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on April 5, 2022 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:46 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 4,000 | $60.90 | $243,600.00 |
DisclosureSEC source: 0001567619-22-018292 · doc1.xml · nonDerivative · entry 2 Garren Hideki · CIK 0001854126 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:46 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionOrdinary Shares, par value $0.01 per share | 4,000 | $24.90 | $99,600.00 |
DisclosureSEC source: 0001567619-22-018292 · doc1.xml · nonDerivative · entry 1 Garren Hideki · CIK 0001854126 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 15, 2022 Filed Sep 16, 2022 21:32 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,000 | $0.00 Strike: $24.90 | $0.00 |
DisclosureSEC source: 0001567619-22-017567 · doc1.xml · derivative · entry 3 Garren Hideki · CIK 0001854126 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 234,000 Underlying: Ordinary Shares · 4,000 shares Expires 2031-04-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on April 5, 2022 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| September 15, 2022 Filed Sep 16, 2022 21:32 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 4,000 | $30.00 | $120,000.00 |
DisclosureSEC source: 0001567619-22-017567 · doc1.xml · nonDerivative · entry 2 Garren Hideki · CIK 0001854126 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| September 15, 2022 Filed Sep 16, 2022 21:32 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionOrdinary Shares, par value $0.01 per share | 4,000 | $24.90 | $99,600.00 |
DisclosureSEC source: 0001567619-22-017567 · doc1.xml · nonDerivative · entry 1 Garren Hideki · CIK 0001854126 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 01, 2022 Filed Aug 3, 2022 21:39 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,000 | $0.00 Strike: $24.90 | $0.00 |
DisclosureSEC source: 0001567619-22-014909 · doc1.xml · derivative · entry 3 Garren Hideki · CIK 0001854126 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 238,000 Underlying: Ordinary Shares · 4,000 shares Expires 2031-04-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on April 5, 2022 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| August 01, 2022 Filed Aug 3, 2022 21:39 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 4,000 | $30.52 | $122,080.00 |
DisclosureSEC source: 0001567619-22-014909 · doc1.xml · nonDerivative · entry 2 Garren Hideki · CIK 0001854126 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| August 01, 2022 Filed Aug 3, 2022 21:39 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionOrdinary Shares, par value $0.01 per share | 4,000 | $24.90 | $99,600.00 |
DisclosureSEC source: 0001567619-22-014909 · doc1.xml · nonDerivative · entry 1 Garren Hideki · CIK 0001854126 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 06, 2022 Filed Jul 8, 2022 21:34 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,000 | $0.00 Strike: $24.90 | $0.00 |
DisclosureSEC source: 0001567619-22-013840 · doc1.xml · derivative · entry 3 Garren Hideki · CIK 0001854126 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,000 Underlying: Ordinary Shares · 8,000 shares Expires 2031-04-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on April 5, 2022 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| July 06, 2022 Filed Jul 8, 2022 21:34 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 8,000 | $30.00 | $240,000.00 |
DisclosureSEC source: 0001567619-22-013840 · doc1.xml · nonDerivative · entry 2 Garren Hideki · CIK 0001854126 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| July 06, 2022 Filed Jul 8, 2022 21:34 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionOrdinary Shares, par value $0.01 per share | 8,000 | $24.90 | $199,200.00 |
DisclosureSEC source: 0001567619-22-013840 · doc1.xml · nonDerivative · entry 1 Garren Hideki · CIK 0001854126 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 23, 2022 Filed Feb 25, 2022 21:31 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantStock Option (Right to Buy) · Derivative | 85,000 | $0.00 Strike: $32.45 | $0.00 |
DisclosureSEC source: 0001140361-22-006895 · form4.xml · derivative · entry 1 Garren Hideki · CIK 0001854126 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,000 Underlying: Ordinary Shares · 85,000 shares Expires 2032-02-23 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on February 23, 2023 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.